Although cisplatin is generally the favoured platinum agent , gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile .
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent , gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile . Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.
### Instruction:
            Given the context about compound efficacy for the given treatment mentioned within the input, mentioned the compounds 
            that can co-occur for the mentioned treatment

            ### Input:
            Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent , gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile . Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

            ### Response:
            cisplatin, gemcitabine, carboplatin
            